RVPH
REVIVA PHARMACEUTICALS HOLDINGS, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 5 ▼ D. Boral Capital downgrades
- Mar 18 Offering: Reviva Pharmaceuticals Holdings, Inc. Announces Proposed P…
- Mar 19 Offering: Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of…
- Mar 19 ▼ Reviva Pharmaceuticals (RVPH) announced the pricing of a public offe…
- Mar 30 Reviva Pharmaceuticals reported financial results for 2025, showing…
- Apr 8 ▼ Maxim Group downgrades
- May 13 ▼ Reviva Pharmaceuticals received a final delisting notice from Nasdaq…
- May 13 ▼ Reviva Pharmaceuticals reported Q1 2026 net loss of $3.2M ($0.46/sha…
- Jul 10 ▼ Nasdaq has filed a Form 25-NSE to remove Reviva Pharmaceuticals Hold…
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- Short sellersSTEADY
Short interest +0.8% to 403.3K shares. 6.7 days to cover.
- TrendDOWNTREND
23% below its 50-day average.
Who's buying
13F| Top holder | Shares | Value |
|---|---|---|
| TD Waterhouse Canada Inc. | 625 | $412.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Apr 2026Price is below the lowest target. Median implies +4894%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Apr 8, 2026 | Maxim Group DOWNGRADE | Hold |
| Mar 31, 2026 | Roth Capital MAINTAIN | Buy |
| Mar 30, 2026 | Alliance Global Partners MAINTAIN | Buy |
| Mar 5, 2026 | D. Boral Capital DOWNGRADE | Hold |
| Jan 5, 2026 | Chardan Capital MAINTAIN | Buy |
| Dec 23, 2025 | D. Boral Capital MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Bhat Laxminarayan President and CEO Mar 18, 2026 | AWARD | 40,925 sh |
Bhat Laxminarayan President and CEO Mar 18, 2026 | AWARD | 109,150 sh |
Prabhu Narayan Chief Financial Officer Mar 18, 2026 | AWARD | 40,925 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | None | None | No data | $0.00 |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
9 filings · 3 press releases · 0 bullish · 3 bearish · 6 neutral- NEUTRAL 8-KNov 12, 2026
Reviva reported Q3 2026 net loss of $2.3M ($0.17 per share), narrower than the $4.0M loss in Q3…
FDA feedback on the new brilaroxazine formulation, expected in Q4 2026, is the next major catalyst. The company's ability to secure additional financing will determine whether RECOVER-2 enrollment…
- NEUTRAL PRESS-RELEASENov 12, 2026
Reviva reported Q3 2026 net loss of $2.3 million ($0.17 per share), narrower than the $4.0 million…
The key catalyst is FDA feedback on the new brilaroxazine formulation expected in Q4 2026, which will determine the path for the RECOVER-2 trial and NDA submission. The company's cash runway of…
- NEUTRAL DEF 14ANov 9, 2026
Reviva Pharmaceuticals Holdings, Inc. filed its definitive proxy statement for the 2026 Annual…
Monitor whether the Board implements the reverse stock split and at what ratio, as this is a prerequisite for a potential Nasdaq uplisting. The company's ability to meet initial listing requirements…
- NEUTRAL PRESS-RELEASEAug 12, 2026
Reviva Pharmaceuticals reported a Q2 2026 net loss of $2.4 million ($0.19 per share), narrower…
The key catalyst is the FDA feedback in Q4 2026 on the new brilaroxazine formulation, which will determine the path for the RECOVER-2 trial and NDA. The company's cash runway and ability to secure…
All RVPH filing & press-release reports (12)
- PRESS-RELEASE reportNov 12, 2026
- 8-K reportNov 12, 2026
- DEF 14A reportNov 9, 2026
- PRESS-RELEASE reportAug 12, 2026
- 25-NSE reportJul 10, 2026
- PRESS-RELEASE reportMay 13, 2026
- 8-K reportMay 13, 2026
- 8-K reportApr 15, 2026
- PRESS-RELEASE reportMar 30, 2026
- PRESS-RELEASE reportMar 18, 2026
- PRESS-RELEASE reportMar 18, 2026
- 8-K reportMar 5, 2026